Literature DB >> 22948748

Decreased hypoxia-inducible factor-1α in gastrocnemius muscle in rats with chronic kidney disease.

Mariusz Flisiński1, Andrzej Brymora, Irena Bartłomiejczyk, Ewa Wiśniewska, Ryszard Gołda, Anna Stefańska, Leszek Pączek, Jacek Manitius.   

Abstract

BACKGROUND/AIMS: Hypoxia-inducible factor (HIF)-1α is responsible for increased expression of genes engaged in angiogenesis. Our previous study indicated capillary rarefaction and atrophy of glycolytic fibers, mainly in locomotor muscles of uremic animals. Perhaps these changes are secondary to disturbances of HIF-1α in skeletal muscles.
METHODS: Expression of HIF-1α at mRNA and protein levels, as well as mRNA of vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS), in gastrocnemius muscle (MG) and longissimus thoracic muscle (ML) were measured by RT-PCR and Western blot. Rats were randomized to subtotal nephrectomy (CKD5/6), uninephrectomy (CKD1/2) or sham operation (controls).
RESULTS: For CKD5/6 versus controls, mRNA levels for HIF-1α, VEGF-A, VEGFR-1 and VEGFR-2 were significantly reduced only in MG, while eNOS was significantly decreased and iNOS was significantly increased only in ML. Western blot analysis indicated significantly increased HIF-1α protein levels in MG and ML from CKD1/2 animals versus controls, whereas in the CKD5/6 group, the level of HIF-1α protein decreased significantly in MG and increased significantly in ML versus controls and CKD1/2.
CONCLUSION: The reduced expression of HIF-1α mRNA and protein in locomotor muscle from CKD5/6 animals may be involved in the pathogenesis of uremic myopathy. Increased expression of iNOS in the postural muscles may act as a protective factor through HIF-1α stabilization.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948748     DOI: 10.1159/000339706

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  6 in total

Review 1.  The renal microcirculation in chronic kidney disease: novel diagnostic methods and therapeutic perspectives.

Authors:  Shulin Li; Fei Wang; Dong Sun
Journal:  Cell Biosci       Date:  2021-05-17       Impact factor: 7.133

2.  Chronic kidney disease induces a systemic microangiopathy, tissue hypoxia and dysfunctional angiogenesis.

Authors:  Hans-Ulrich Prommer; Johannes Maurer; Karoline von Websky; Christian Freise; Kerstin Sommer; Hamoud Nasser; Rudi Samapati; Bettina Reglin; Pedro Guimarães; Axel Radlach Pries; Uwe Querfeld
Journal:  Sci Rep       Date:  2018-03-28       Impact factor: 4.379

Review 3.  Mechanisms and Modulation of Oxidative/Nitrative Stress in Type 4 Cardio-Renal Syndrome and Renal Sarcopenia.

Authors:  Márta Sárközy; Zsuzsanna Z A Kovács; Mónika G Kovács; Renáta Gáspár; Gergő Szűcs; László Dux
Journal:  Front Physiol       Date:  2018-11-26       Impact factor: 4.566

4.  Muscle fibrosis and maladaptation occur progressively in CKD and are rescued by dialysis.

Authors:  Camille R Brightwell; Ameya S Kulkarni; William Paredes; Kehao Zhang; Jaclyn B Perkins; Knubian J Gatlin; Matthew Custodio; Hina Farooq; Bushra Zaidi; Rima Pai; Rupinder S Buttar; Yan Tang; Michal L Melamed; Thomas H Hostetter; Jeffrey E Pessin; Meredith Hawkins; Christopher S Fry; Matthew K Abramowitz
Journal:  JCI Insight       Date:  2021-12-22

Review 5.  Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity.

Authors:  Uwe Querfeld; Robert H Mak; Axel Radlach Pries
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

6.  Alteration autonomic control of cardiac function during hemodialysis predict cardiovascular outcomes in end stage renal disease patients.

Authors:  Chih-Chin Kao; Chi-Ho Tseng; Men-Tzung Lo; Ying-Kuang Lin; Chien-Yi Hsu; Yueh-Lin Wu; Hsi-Hsien Chen; Feng-Yen Lin; Chen Lin; Chun-Yao Huang
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.